Zenas BioPharma, Inc. (ZBIO) company profile
Close on Nov 17, 2026Market cap $1.81BP/E –Yield –
About Zenas BioPharma
Pharmaceutical Preparations, SIC 2834
Zenas is a clinical-stage biopharmaceutical company that develops therapies for patients with autoimmune and inflammatory diseases. It acquires and develops product candidates directed at immune targets, without having any approved commercial products or sales revenue. Its lead candidate, obexelimab, is a monoclonal antibody that inhibits B-cell activity without cell destruction for conditions including immunoglobulin G4-related disease, relapsing multiple sclerosis, and systemic lupus erythematosus. The company also advances orelabrutinib for progressive forms of multiple sclerosis, along with early-stage candidates ZB021 and ZB022. Its end users are patients suffering from autoimmune conditions.
The provided text does not disclose the company's headquarters location. Operationally, the firm conducts clinical trials internationally across several countries, including the United States, the United Kingdom, Hungary, Poland, the Czech Republic, and Slovakia, dosing hundreds of clinical subjects. It maintains worldwide development rights for select pipeline assets while partnering with pharmaceutical companies across regional markets, including greater China and parts of the Asia-Pacific region.
Summary of the business section of Zenas BioPharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Zenas BioPharma, Inc.
- Headquarters
- Waltham, MA
- Address
- 852 Winter Street, Suite 250 02451
- Phone
- (857) 271-2954
- Website
- zenasbio.com
- Employees
- 167, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ZBIO
- Exchange
- Nasdaq
- IPO date
- Sep 13, 2024
- Shares outstanding
- 65M, Jul 31, 2026
- Public float
- $259.30M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1953926
- CUSIP
- 98937L105
- ISIN
- US98937L1052
- FIGI
- BBG01J1MG9D6
- Share class FIGI
- BBG01J1MG9F4
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Leon O. Moulder Jr | See Remarks, Director | 520,083 |
| Moltke Lisa von | See Remarks | – |
| Joseph L. Farmer | See Remarks | 974 |
| Jennifer A. Fox | See Remarks | 1,592 |
| Orlando Oliveira | See Remarks | – |
| Christy J. Oliger | Director | – |
| John J. Orloff | Director | – |
| Patrick G. Enright | Director | 1,844,659 |
| Jason Raleigh Nunn | Director | 3,119,959 |
| Patricia L. Allen | Director | 19,860 |
| James P. Boylan | Director | – |
| Hongbo Lu | Director | 426,736 |
| Funds Management LLC Fairmount | Director | 1,892,806 |
| Tomas Kiselak | Director | 2,359,025 |
| Healthcare Fund II L.P. Fairmount | Director | 287,915 |
| Peter Evan Harwin | Director | 2,209,025 |
| Ting Xiao | Director | 10,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Leon O. Moulder, Jr. Founder, Chief Executive Officer and Chairman | $520.00K | – | $3.77M | $371.80K | – | $4.66M | -77% |
| Joseph L. Farmer President and Chief Operating Officer | $520.00K | – | $1.65M | $336.70K | $20.80K | $2.53M | -58% |
| Lisa von Moltke, M.D. Head of Research and Development and Chief Medical Officer | $411.67K | $347.90K | $2.74M | – | – | $3.50M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 13, 2024
- Offer price
- $17.00
- Securities offered
- 13,235,294
- Gross proceeds
- $225.00M
- Exchange
- Nasdaq
- First trading day
- Sep 13, 2024
- First-day close
- $18.15+6.8%
- Lock-up ends (est.)
- Mar 12, 2025
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 28, 2026, we had 167 full-time employees, consisting of clinical, scientific, development, medical affairs, technical operations, regulatory, finance, legal and operational personnel.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 2, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Sep 13, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 10, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 15, 2022 | Name change | Name changed from Zenas BioPharma (Cayman) Ltd to Zenas BioPharma, Inc. |
See a number that looks wrong?